BMO Capital Downgrades Bristol-Myers Squibb Co. (BMY) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/21/2026
- Wall St futures gain on Iran ceasefire hopes; earnings in focus
- Oil prices firm as investors weigh fresh attacks against potential US-Iran ceasefire
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
BMO Capital Upgrades Merck (MRK) to Outperform
November 12, 2012 7:27 AM ESTBMO Capital upgraded Merck (NYSE: MRK) from Market Perform to Outperform with a price target of $50.00.
NOTE: The firm downgraded BMY today.
For an analyst ratings summary and ratings history on Merck... More
